Taiho’s Cholangiocarcinoma Drug Gets Breakthrough Therapy Tag from FDA

Taiho Pharmaceutical said on April 2 that its FGFR inhibitor futibatinib has obtained the US FDA’s Breakthrough Therapy designation for the treatment of certain patients with advanced or metastatic cholangiocarcinoma. The status was given to treat patients with previously treated...read more